Navigation Links
Northfield Laboratories Reports Results of Pivotal Phase III Trauma,Study

k following traumatic injuries beginning in the prehospital setting. Treatment began at the scene of injury, continued in the ambulance during transport, and for up to 12 hours post-injury or a total of 6 units. Patients then received donated blood if they continued to bleed. Patients in the control group received the standard of care: saline in the field and during transport, followed by blood upon arrival at the hospital. Thirty-two Level I trauma centers participated in the study, which was conducted to seek an indication for the use of PolyHeme that addresses a critical, unmet medical need: the unavailability of blood.

In December 2006, Northfield announced that it had received the preliminary draft top-line data from its contract research organization. Northfield indicated that due to certain discrepancies in the data identified during its initial review, it became necessary to resolve the discrepancies and unlock the study database to make any necessary corrections. The process has now been completed, the study database relocked, and the data reanalyzed. Northfield has also had the opportunity to further analyze the study data, including additional safety data. These data have not been submitted to or reviewed by FDA.

About Northfield Laboratories

Northfield Laboratories, Inc., is a leader in developing an oxygen-carrying red blood cell substitute for the treatment of life-threatening blood loss, when an oxygen-carrying fluid is required and red blood cells are not available. PolyHeme(R) is a solution of chemically modified human hemoglobin that requires no cross matching and is, therefore, compatible with all blood types. It has a shelf life in excess of 12 months. For further information, visit www.northfieldlabs.com.

Forward Looking Statement

This press release may contain forward-looking statements concerning, among other things, Northfield's future business plans and strategies and clinical and regulatory developments af
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Northfield Laboratories Investor Update
2. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
3. Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Positive Results of Phase III Study for Milnacipran as a Treatment for Fibromyalgia Syndrome
4. Columbia Laboratories Reports Preliminary Findings from the Ongoing Data Analysis of the Phase III Clinical Study of PROCHIEVE 8% (progesterone gel) to Prevent Preterm Birth
5. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
6. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
7. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
8. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
9. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
10. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
11. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
Post Your Comments:
(Date:8/29/2014)... 29, 2014  United Therapeutics Corporation (NASDAQ: ... for the District of New Jersey ... case against Sandoz, Inc. regarding United Therapeutics, Remodulin ® ... ruled that U.S. Patent No. 6,765,117 is both valid ... marketing its generic product until the expiration of that ...
(Date:8/29/2014)... -- Diseases largely eradicated in the United ... was declared eliminated in 2000, yet the CDC reports ... highest incidence in 20 years. In July, ... a problem of "epidemic proportions." ... these preventable diseases—in part because some parents (more than ...
(Date:8/29/2014)... DUBLIN , Aug. 29, 2014 ... the "Global Multiple Sclerosis Drugs Market 2014-2018" ... is a chronic, inflammatory medical condition that results in ... damaged because of an abnormal response by the immune ... (CNS). It is a potentially debilitating disease in which ...
Breaking Medicine Technology:District Court Decision Received In Remodulin Patent Case 2Vaccines at the Crossroads: Outbreaks On the Rise Across America 2Vaccines at the Crossroads: Outbreaks On the Rise Across America 3Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 3
... Ala., Dec. 14 BioCryst,Pharmaceuticals, Inc. (Nasdaq: ... data evaluating forodesine HCl, the Company,s lead anti-cancer,compound, ... and lymphomas., Madeline Duvic, M.D., Deputy Chair, ... presented interim data from the Phase,I/II clinical study ...
... the Treatment of PKU, NOVATO, Calif., Dec. ... announced today that the U.S.,Food and Drug Administration ... Tablets, the first specific drug,therapy approved for the ... will commence tomorrow, and BioMarin will begin,promotion of ...
Cached Medicine Technology:Data Presented at 2007 ASH Meeting Demonstrate Activity of Forodesine HCl as a Single Agent or in Combination With Bendamustine in Certain Types of Leukemia and Lymphoma 2Data Presented at 2007 ASH Meeting Demonstrate Activity of Forodesine HCl as a Single Agent or in Combination With Bendamustine in Certain Types of Leukemia and Lymphoma 3Data Presented at 2007 ASH Meeting Demonstrate Activity of Forodesine HCl as a Single Agent or in Combination With Bendamustine in Certain Types of Leukemia and Lymphoma 4BioMarin Announces FDA Approval for Kuvan 2BioMarin Announces FDA Approval for Kuvan 3BioMarin Announces FDA Approval for Kuvan 4BioMarin Announces FDA Approval for Kuvan 5BioMarin Announces FDA Approval for Kuvan 6BioMarin Announces FDA Approval for Kuvan 7BioMarin Announces FDA Approval for Kuvan 8
(Date:8/29/2014)... a systematic review of clinical trials based on ... researchers have concluded that more trials are needed ... for postsurgical pain on a regular basis., Dr. ... pain research in the Department of Anesthesiology, and ... to determine whether the use of antidepressants for ...
(Date:8/29/2014)... Colo. (Sept. 2, 2014) A team of scientists ... reported the breakthrough discovery of a process to expand ... These findings could have implications that extend beyond cancer, ... autoimmune diseases., In an article published Aug. ... Charles C. Gates Center for Regenerative Medicine and Stem ...
(Date:8/29/2014)... Mass. (August 29, 2014, 2 PM US Eastern ... is to inject antibodies, commonly produced in animals, ... challenges ranging from safety to difficulties in developing, ... , New research led by Charles Shoemaker, ... and Global Health at the Cummings School of ...
(Date:8/29/2014)... EDMONTON, AB A new study from the research group ... AB) and the Lawson Health Research Institute (London, ON) has ... of cancer. The study, published in Cell Reports , ... spread of cancer entirely. , Roughly 2 in 5 ... four of them will die of the disease. In 2014, ...
(Date:8/29/2014)... Francisco, CA (PRWEB) August 30, 2014 ... 10 best web conference providers in the online service ... the list were global leaders Webex, GotoMeeting and Infinite. ... the industry users have to determine which provider is ... Essentially, web conference businesses search for compelling consumer goods ...
Breaking Medicine News(10 mins):Health News:Antidepressants show potential for postoperative pain 2Health News:CU scientists' discovery could lead to new cancer treatment 2Health News:Mice study shows efficacy of new gene therapy approach for toxin exposures 2Health News:Preventing cancer from forming 'tentacles' stops dangerous spread 2Health News:Top10InAction Reveals Best Web Conference Providers 2
... WASHINGTON, Sept. 2 Speaker Nancy Pelosi and Senate Majority Leader Harry Reid ... Session of Congress on Wednesday, September 9, 2009. , , ... , September 2, 2009 , , President Barack ... Dear Mr. President: , , Our nation is closer than ever ...
... ATLANTA, Sept. 2 /PRNewswire-FirstCall/ -- Gentiva Health Services, Inc. ... health services, announced today that it has completed its acquisition of ... the Rush Health System, located in central Mississippi and west central ... , "We extend a warm welcome to all ...
... , , WASHINGTON, Sept. ... President, Campaign for Tobacco-Free Kids: , , (Logo: ... have taken decisive action to protect the state,s kids and taxpayers from ... by $1 to $3.00 per pack, making it the second highest state ...
... Study found more than half of advanced basal cell carcinomas ... -- An experimental cancer drug that switches off the so-called ... patients with advanced basal cell carcinoma, a type of skin ... from medulloblastoma, the most common form of brain cancer in ...
... , OAKLAND, Calif., Sept. 2 Wigix ( ... database on the web. Wigix has surpassed Overstock.com and ... (Source: Internet Retailers Top 500 Guide 2009 Edition) , , ... thousand SKUs during its public beta launch in June 2007. This milestone marks ...
... , , , ... the House Democrat healthcare bill (H.R. 3200) that violate President Obama,s promise ... $250,000 per year. The White House has told reporters that Obama ... week, which begs the question: , , ...
Cached Medicine News:Health News:Gentiva(R) Health Services Completes Acquisition of Home Health Agency 2Health News:Gentiva(R) Health Services Completes Acquisition of Home Health Agency 3Health News:Connecticut Cigarette Tax Increase Delivers Victory for Kids and Taxpayers; $1 Increase Gives State Second Highest Cigarette Tax in the Nation 2Health News:Connecticut Cigarette Tax Increase Delivers Victory for Kids and Taxpayers; $1 Increase Gives State Second Highest Cigarette Tax in the Nation 3Health News:New Compound Shrinks Skin Cancers 2Health News:New Compound Shrinks Skin Cancers 3Health News:New Compound Shrinks Skin Cancers 4Health News:Wigix Announces 1 Million in Open Sell Orders 2Health News:Obama's 'Specific' Healthcare Speech: Will He Disavow Pledge-Breaking Tax Hikes in House Dem Health Bill? 2
Stainless steel construction to withstand sterilization modalities (EtO) Wide angle of view...
Inquire...
ENDOlap™ laparoscopes provide excellent image linearity and flatness of field....
The Fujinon's R410 laparoscope is the first to bring a 410,000 pixel CCD to the end of the scope. Superior imaging and color replication, along with a unique lens washing capability make the R410 the...
Medicine Products: